Digital PCR techniques are ideally suited for accurately quantifying trace amounts of target DNA sequences, such as tumor-derived mutant DNA that is present in the blood circulation of patients with cancer. Here, we describe an approach marrying low-coverage whole-genome sequencing of tumor tissues, to enumerate chromosomal rearrangement breakpoints, together with droplet digital PCR (ddPCR)-based personalized rearrangement assays to cost-effectively monitor circulating tumor DNA levels at multiple time-points during the clinical course. The method is generally applicable to essentially any cancer patient, as all cancers harbor unstable genomes, and may have uses for measuring minimal residual disease, response to therapy, and early detection of metastasis.
CITATION STYLE
Chen, Y., George, A. M., Olsson, E., & Saal, L. H. (2018). Identification and use of personalized genomic markers for monitoring circulating tumor DNA. In Methods in Molecular Biology (Vol. 1768, pp. 303–322). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7778-9_17
Mendeley helps you to discover research relevant for your work.